Trehalose and aortic inflammatio
Phase 2
Recruiting
- Conditions
- Aortic inflammation in patients with cancer.Arteritis, unspecifiedI77.6
- Registration Number
- IRCT20130829014521N20
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
Cancer patients with aortic inflammation with a cutoff of 1.6 or more for the TBR in the first scan
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Investigation of aortic inflammation with (18F-FDG PET) scan. Timepoint: one week after administration of trehalose. Method of measurement: (18F-FDG PET) scan.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Trehalose's anti-inflammatory effects in aortic inflammation among cancer patients?
How does Trehalose compare to standard-of-care treatments for aortic inflammation in oncology settings?
Are there specific biomarkers that predict response to Trehalose in aortic inflammation associated with cancer?
What are the known or potential adverse events of Trehalose in Phase II trials for aortic inflammation in cancer patients?
What combination therapies or alternative compounds show promise in treating aortic inflammation in cancer patients alongside Trehalose?